gefitinib has been researched along with Choroid Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ajithkumar, T; Geropantas, K; Glenn, A; Kouroupis, M; Maskell, D | 1 |
| Bar-Eli, M; Bassett, RL; Bedikian, AY; Bronstein, Y; Dobroff, A; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Patel, SP; Prieto, VG; Vardeleon, AG; Zigler, M | 1 |
1 review(s) available for gefitinib and Choroid Neoplasms
| Article | Year |
|---|---|
Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: radiotherapy or TKIs?
Topics: Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
1 trial(s) available for gefitinib and Choroid Neoplasms
| Article | Year |
|---|---|
A phase II study of gefitinib in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Choroid Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Texas; Time Factors; Treatment Outcome; Young Adult | 2011 |